Pembrolizumab Combo Yields Benefits in pMMR/dMMR Advanced Endometrial CancerMarch 28th 2023
Pembrolizumab plus chemotherapy followed by maintenance pembrolizumab reduced the risk of death or disease progression in patients with mismatch repair proficient or deficient advanced endometrial cancer.
Questionnaires Are Comparable in Assessing Lymphedema in Endometrial CancerMarch 27th 2023
The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.
Dose Modification of Maintenance Niraparib May Not Impact PFS in Ovarian CancerMarch 27th 2023
A post hoc analysis demonstrated that dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival among patients with newly diagnosed, advanced ovarian cancer.
Addition of Dual Checkpoint Blockade Inhibition Improves PFS in Ovarian CancerMarch 27th 2023
Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.
Adding HIPEC to Cytoreductive Surgery Does Not Impact HRQOL in Ovarian CancerMarch 25th 2023
Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.
Jhalak Dholakia, MD, Spotlights Ongoing Trial of Neoadjuvant Mirvetuximab Soravtansine in FRα-High Ovarian CancerMay 3rd 2022
An ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.
Ursula A. Matulonis, MD, on the Safety of Mirvetuximab Soravtansine in FRα-High Ovarian CancerApril 22nd 2022
In an interview with CancerNetwork®, Ursula A. Matulonis, MD, discusses the toxicities associated with mirvetuximab soravtansine in folate receptor α–high platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, on Key Findings With Mirvetuximab Soravtansine in FRα-High Ovarian CancerApril 14th 2022
Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.
Jyoti S. Mayadev, MD, on Atezolizumab for Locally Advanced, Node-Positive Cervical CancerApril 7th 2022
At SGO 2022, Jyoti S. Mayadev, MD presented results of the NRG-GY017 trial of atezolizumab as either an immune primer or with chemoradiation for certain patients with locally advanced cervical cancer.
Ursula A. Matulonis, MD, Highlights the Potential of Mirvetuximab Soravtansine in FRα-High Ovarian CancerApril 6th 2022
In a discussion with CancerNetwork®, Ursula A. Matulonis, MD, describes the potential of mirvetuximab soravtansine (IMGN853) as a treatment for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.